8 March 2023 - The application is based on phase III results from the DINAMO trial showing Jardiance (empagliflozin) tablets significantly reduced A1c versus placebo in participants aged 10-17 living with type 2 diabetes.
The US FDA accepted a supplemental new drug application for Jardiance (empagliflozin) investigating a potential new indication to lower blood sugar along with diet and exercise in children 10 years and older with type 2 diabetes, Boehringer Ingelheim and Eli Lilly have announced.